Skip to main content
Top
Published in: Current Treatment Options in Oncology 2/2020

01-02-2020 | Nausea | Palliative and Supportive Care (MP Davis, Section Editor)

Nausea and Vomiting in Advanced Cancer

Author: Rudolph M. Navari, MD, PhD, FACP

Published in: Current Treatment Options in Oncology | Issue 2/2020

Login to get access

Opinion Statement

Nausea and vomiting is a common clinical issue in the advanced cancer patient. The etiology may be related to treatment (chemotherapy, radiation, surgery) or non-treatment clinical issues related to the advanced cancer. A very detailed initial assessment of nausea/vomiting is indicated including frequency, duration, intensity, associated activities, and the presence of anorexia or cachexia and is necessary in order to determine a specific etiology which may allow a potentially specific successful intervention. Various international antiemetic guidelines have been developed for the successful prevention of chemotherapy- and radiotherapy-induced nausea and emesis but the treatment of post-chemotherapy nausea/vomiting and of radiation-induced nausea/vomiting has been less successful. Chronic nausea/vomiting in the advanced cancer patient unrelated to treatment remains a significant clinical problem with few successful treatments and interventions. NCCN and ASCO palliative care guidelines provide various treatment suggestions but these are based on empiric evidence with very few clinical trials available to provide demonstrated effective treatments. Recent randomized clinical trials have demonstrated that olanzapine may be an effective agent for the prevention and treatment of chemotherapy-induced nausea and emesis as well as treatment of chronic nausea and vomiting unrelated to treatment.
Literature
1.•
go back to reference NCCN Clinical practice guidelines in oncology. Palliative care version 2.2019; 2019. Accessed 7/15/2019. Recommendations for treatment of nausea and vomiting in advanced cancer patients. NCCN Clinical practice guidelines in oncology. Palliative care version 2.2019; 2019. Accessed 7/15/2019. Recommendations for treatment of nausea and vomiting in advanced cancer patients.
2.•
go back to reference Navari RM. Managing nausea and vomiting in patients with cancer: what works. Oncology (Williston Park). 2018;32:121–5 31, 36. Clinical approach to treatment of nausea in advanced cancer patients. Navari RM. Managing nausea and vomiting in patients with cancer: what works. Oncology (Williston Park). 2018;32:121–5 31, 36. Clinical approach to treatment of nausea in advanced cancer patients.
3.
go back to reference Davis MP, Hallerberg G, Palliative Medicine Study Group of the Multinational Association of Supportive Care in C. A systematic review of the treatment of nausea and/or vomiting in cancer unrelated to chemotherapy or radiation. J Pain Symptom Manag. 2010;39:756–67.CrossRef Davis MP, Hallerberg G, Palliative Medicine Study Group of the Multinational Association of Supportive Care in C. A systematic review of the treatment of nausea and/or vomiting in cancer unrelated to chemotherapy or radiation. J Pain Symptom Manag. 2010;39:756–67.CrossRef
4.
go back to reference Delgado-Guay MO, Parsons HA, Li Z, Palmer LJ, Bruera E. Symptom distress, interventions, and outcomes of intensive care unit cancer patients referred to a palliative care consult team. Cancer. 2009;115:437–45.CrossRef Delgado-Guay MO, Parsons HA, Li Z, Palmer LJ, Bruera E. Symptom distress, interventions, and outcomes of intensive care unit cancer patients referred to a palliative care consult team. Cancer. 2009;115:437–45.CrossRef
5.
go back to reference Gupta M, Davis M, LeGrand S, Walsh D, Lagman R. Nausea and vomiting in advanced cancer: the Cleveland Clinic protocol. J Support Oncol. 2013;11:8–13.PubMed Gupta M, Davis M, LeGrand S, Walsh D, Lagman R. Nausea and vomiting in advanced cancer: the Cleveland Clinic protocol. J Support Oncol. 2013;11:8–13.PubMed
6.
go back to reference Digges M, Hussein A, Wilcock A, Crawford GB, Boland JW, Agar MR, et al. Pharmacovigilance in hospice/palliative care: net effect of haloperidol for nausea or vomiting. J Palliat Med. 2018;21:37–43.CrossRef Digges M, Hussein A, Wilcock A, Crawford GB, Boland JW, Agar MR, et al. Pharmacovigilance in hospice/palliative care: net effect of haloperidol for nausea or vomiting. J Palliat Med. 2018;21:37–43.CrossRef
7.
go back to reference Bruera E, Moyano JR, Sala R, Rico MA, Bosnjak S, Bertolino M, et al. Dexamethasone in addition to metoclopramide for chronic nausea in patients with advanced cancer: a randomized controlled trial. J Pain Symptom Manag. 2004;28:381–8.CrossRef Bruera E, Moyano JR, Sala R, Rico MA, Bosnjak S, Bertolino M, et al. Dexamethasone in addition to metoclopramide for chronic nausea in patients with advanced cancer: a randomized controlled trial. J Pain Symptom Manag. 2004;28:381–8.CrossRef
8.
go back to reference Hardy JR, Skerman H, Phillip J, et al. Methotrimeprazine versus haloperidol in palliative care patients with cancer-related nausea; a randomized double-blind controlled trial. BMJ Open. 2019;9:e029942.CrossRef Hardy JR, Skerman H, Phillip J, et al. Methotrimeprazine versus haloperidol in palliative care patients with cancer-related nausea; a randomized double-blind controlled trial. BMJ Open. 2019;9:e029942.CrossRef
9.
go back to reference Hardy J, Skerman H, Glare P, et al. A randomized open-label study of guideline-driven antiemetic therapy versus single agent antiemetic therapy in patients with advanced cancer and nausea not related to anticancer treatment. BMC Cancer. 2018;18:510.CrossRef Hardy J, Skerman H, Glare P, et al. A randomized open-label study of guideline-driven antiemetic therapy versus single agent antiemetic therapy in patients with advanced cancer and nausea not related to anticancer treatment. BMC Cancer. 2018;18:510.CrossRef
10.
go back to reference Matsuoka H, Agar M, Vandersman Z, et al. Harms from haloperidol for symptom management in palliative care - a post hoc pooled analysis of three randomized controlled studies and two consecutive cohort studies. J Pain Symptom Manage. 2019;58:e6–8.CrossRef Matsuoka H, Agar M, Vandersman Z, et al. Harms from haloperidol for symptom management in palliative care - a post hoc pooled analysis of three randomized controlled studies and two consecutive cohort studies. J Pain Symptom Manage. 2019;58:e6–8.CrossRef
11.
go back to reference Navari RM, Aapro M. Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting. N Engl J Med. 2016;374:1356–67.CrossRef Navari RM, Aapro M. Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting. N Engl J Med. 2016;374:1356–67.CrossRef
12.
go back to reference Navari RM, Schwartzberg L. Evolving role of neurokinin 1 receptor antagonists for chemotherapy-induced nausea and vomiting. OncoTargets Ther. 2018;11:6459–78.CrossRef Navari RM, Schwartzberg L. Evolving role of neurokinin 1 receptor antagonists for chemotherapy-induced nausea and vomiting. OncoTargets Ther. 2018;11:6459–78.CrossRef
13.
go back to reference Navari RM. Treatment of chemotherapy-induced nausea. Commun Oncol. 2012;9:20–6.CrossRef Navari RM. Treatment of chemotherapy-induced nausea. Commun Oncol. 2012;9:20–6.CrossRef
14.
go back to reference Ng TL, Hutton B, Clemons M. Chemotherapy-induced nausea and vomiting. Time for more emphasis on nausea? Oncologist. 2015;20:576–83.CrossRef Ng TL, Hutton B, Clemons M. Chemotherapy-induced nausea and vomiting. Time for more emphasis on nausea? Oncologist. 2015;20:576–83.CrossRef
15.
go back to reference Glare P, Miller J, Nikolova T, et al. Treating nausea and vomiting in palliative care: a review. Clin Interv Aging. 2011;6:243–59.CrossRef Glare P, Miller J, Nikolova T, et al. Treating nausea and vomiting in palliative care: a review. Clin Interv Aging. 2011;6:243–59.CrossRef
16.
go back to reference Smith HS, Smith JM, Smith AR. An overview of nausea/vomiting in palliative medicine. Ann Palliat Med. 2012;1:103–14.PubMed Smith HS, Smith JM, Smith AR. An overview of nausea/vomiting in palliative medicine. Ann Palliat Med. 2012;1:103–14.PubMed
17.•
go back to reference NCCN Practice guidelines in oncology. Antiemesis version 1.2019 - February 28, 2019. Recommendatiosn for treatment of CINV. NCCN Practice guidelines in oncology. Antiemesis version 1.2019 - February 28, 2019. Recommendatiosn for treatment of CINV.
18.•
go back to reference Walsh D, Davis D, Ripoamonti C, et al. 2016 Updated MASCC/ESMO consensus recommendations management of nauea and vomiting in advanced cancer patients. Spport Care Cancer. 2017:333–40. Recommendations for treatment of nausea and vomiting in advanced cancer patients. Walsh D, Davis D, Ripoamonti C, et al. 2016 Updated MASCC/ESMO consensus recommendations management of nauea and vomiting in advanced cancer patients. Spport Care Cancer. 2017:333–40. Recommendations for treatment of nausea and vomiting in advanced cancer patients.
19.
go back to reference Hesketh PJ, Kris MG, Basch E, et al. ASCO antiemetic guidelines. J Clin Oncol. 2017;35:3240–61.CrossRef Hesketh PJ, Kris MG, Basch E, et al. ASCO antiemetic guidelines. J Clin Oncol. 2017;35:3240–61.CrossRef
20.
go back to reference Navari RM, Brenner MC. Treatment of cancer related anorexia with megestrol acetate and olanzapine. Support Care Cancer. 2010;18:951–6.CrossRef Navari RM, Brenner MC. Treatment of cancer related anorexia with megestrol acetate and olanzapine. Support Care Cancer. 2010;18:951–6.CrossRef
21.
go back to reference Navari RM, Qin R, Ruddy KJ, Liu H, Powell SF, Bajaj M, et al. Olanzapine for the prevention of chemotherapy-induced nausea and vomiting. N Engl J Med. 2016;375:134–42.CrossRef Navari RM, Qin R, Ruddy KJ, Liu H, Powell SF, Bajaj M, et al. Olanzapine for the prevention of chemotherapy-induced nausea and vomiting. N Engl J Med. 2016;375:134–42.CrossRef
22.
go back to reference Navari RM, Nagy CK, Gray SE. The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer. 2013;21:1655–63.CrossRef Navari RM, Nagy CK, Gray SE. The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer. 2013;21:1655–63.CrossRef
23.
go back to reference Prommer E. Olanzapine: palliative medicine update. Am J Hosp Palliat Med. 2012;30:75–82.CrossRef Prommer E. Olanzapine: palliative medicine update. Am J Hosp Palliat Med. 2012;30:75–82.CrossRef
24.
go back to reference Jackson WC, Tavernier L. Olanzapine for intractable nausea in palliative care patients. J Palliat Med. 2003;6:251–5.CrossRef Jackson WC, Tavernier L. Olanzapine for intractable nausea in palliative care patients. J Palliat Med. 2003;6:251–5.CrossRef
25.
go back to reference Kaneishi K, Kawabata M, Morita T. Olanzapine for the relief of nausea in patients with advanced cancer and incomplete bowel obstruction. J Pain Symptom Manag. 2012;44:604–7.CrossRef Kaneishi K, Kawabata M, Morita T. Olanzapine for the relief of nausea in patients with advanced cancer and incomplete bowel obstruction. J Pain Symptom Manag. 2012;44:604–7.CrossRef
26.
go back to reference Licup N. Olanzapine for nausea and vomiting. Am J Hosp Palliat Care. 2010;27:432–4.CrossRef Licup N. Olanzapine for nausea and vomiting. Am J Hosp Palliat Care. 2010;27:432–4.CrossRef
27.
go back to reference Passik SD, Kirsh KL, Theobald DE, Dickerson P, Trowbridge R, Gray D, et al. A retrospective chart review of the use of olanzapine for the prevention of delayed emesis in cancer patients. J Pain Symptom Manag. 2003;25:485–8.CrossRef Passik SD, Kirsh KL, Theobald DE, Dickerson P, Trowbridge R, Gray D, et al. A retrospective chart review of the use of olanzapine for the prevention of delayed emesis in cancer patients. J Pain Symptom Manag. 2003;25:485–8.CrossRef
28.
go back to reference Pirl WF, Roth AJ. Remission of chemotherapy-induced emesis with concurrent olanzapine treatment: a case report. Psychooncology. 2000;9:84–7.CrossRef Pirl WF, Roth AJ. Remission of chemotherapy-induced emesis with concurrent olanzapine treatment: a case report. Psychooncology. 2000;9:84–7.CrossRef
29.
go back to reference Srivastava M, Brito-Dellan N, Davis MP, Leach M, Lagman R. Olanzapine as an antiemetic in refractory nausea and vomiting in advanced cancer. J Pain Symptom Manag. 2003;25:578–82.CrossRef Srivastava M, Brito-Dellan N, Davis MP, Leach M, Lagman R. Olanzapine as an antiemetic in refractory nausea and vomiting in advanced cancer. J Pain Symptom Manag. 2003;25:578–82.CrossRef
30.
go back to reference Passik SD, Lundberg J, Kirsh KL, Theobald D, Donaghy K, Holtsclaw E, et al. A pilot exploration of the antiemetic activity of olanzapine for the relief of nausea in patients with advanced cancer and pain. J Pain Symptom Manag. 2002;23:526–32.CrossRef Passik SD, Lundberg J, Kirsh KL, Theobald D, Donaghy K, Holtsclaw E, et al. A pilot exploration of the antiemetic activity of olanzapine for the relief of nausea in patients with advanced cancer and pain. J Pain Symptom Manag. 2002;23:526–32.CrossRef
31.
go back to reference Bosnjak SM, Dimitrijevic J, Djordjevic F. Cancer and chemotherapy-induced nausea and vomiting: a focus on olanzapine. Curr Opin Support Palliat Care. 2016;10:180–8.CrossRef Bosnjak SM, Dimitrijevic J, Djordjevic F. Cancer and chemotherapy-induced nausea and vomiting: a focus on olanzapine. Curr Opin Support Palliat Care. 2016;10:180–8.CrossRef
32.
go back to reference Navari RM. Olanzapine for the prevention and treatment of chronic nausea and chemotherapy-induced nausea and vomiting. Eur J Pharmacol. 2014;722:180–6.CrossRef Navari RM. Olanzapine for the prevention and treatment of chronic nausea and chemotherapy-induced nausea and vomiting. Eur J Pharmacol. 2014;722:180–6.CrossRef
33.••
go back to reference Navari RM, Pywell CM, Le-Rademacher JG, et al. Olanzapine for the treatment of advanced cancer-related chronic nausea and/or vomiting. ASCP Palliative Care Symposium San Francisco, October, 2019. Randomized clinicaltrial demonstrating the effectiveness of olanzapine in chronic nausea in advanced cancer patients. Navari RM, Pywell CM, Le-Rademacher JG, et al. Olanzapine for the treatment of advanced cancer-related chronic nausea and/or vomiting. ASCP Palliative Care Symposium San Francisco, October, 2019. Randomized clinicaltrial demonstrating the effectiveness of olanzapine in chronic nausea in advanced cancer patients.
34.
go back to reference Molassiotis A, Aapro M, Herrstedt, et al. MASCC/ESMO antiemetics guidelines: introduction to the 2016 guideline update. Support Care Cancer. 2017;25:267–9.CrossRef Molassiotis A, Aapro M, Herrstedt, et al. MASCC/ESMO antiemetics guidelines: introduction to the 2016 guideline update. Support Care Cancer. 2017;25:267–9.CrossRef
35.
go back to reference Navari RM. Should behavioral therapy be used as the primary treatment to control anticipatory vomiting? HemeOnc Today. 2016;17:13. Navari RM. Should behavioral therapy be used as the primary treatment to control anticipatory vomiting? HemeOnc Today. 2016;17:13.
36.
go back to reference Navari RM. Cancer patients at high risk for chemotherapy-induced nausea and vomiting - prediction assessment/tools. Expert Rev Quality Cancer Care. 2017;2:102–8. Navari RM. Cancer patients at high risk for chemotherapy-induced nausea and vomiting - prediction assessment/tools. Expert Rev Quality Cancer Care. 2017;2:102–8.
37.
go back to reference Kamen C, Mohamedtaki A, Tejani KC, et al. Anticipatory nausea and vomiting due to chemotherapy. Eur J Pharmacol. 2014;722:172–9.CrossRef Kamen C, Mohamedtaki A, Tejani KC, et al. Anticipatory nausea and vomiting due to chemotherapy. Eur J Pharmacol. 2014;722:172–9.CrossRef
38.
go back to reference Dennis K, Rehana J, McGrath C, et al. A systematic review of methodologies, endpoints, and outcome measures in randomized trials of radiation therapy-induced nausea and vomiting. Support Care Cancer. 2017;25:2019–33.CrossRef Dennis K, Rehana J, McGrath C, et al. A systematic review of methodologies, endpoints, and outcome measures in randomized trials of radiation therapy-induced nausea and vomiting. Support Care Cancer. 2017;25:2019–33.CrossRef
39.
go back to reference Chiu N, Chiu L, Popovic M, et al. Latest advances in the management of radiation-induced pain flare, nausea and vomiting. Ann Palliat Med. 2016;5:50–7.PubMed Chiu N, Chiu L, Popovic M, et al. Latest advances in the management of radiation-induced pain flare, nausea and vomiting. Ann Palliat Med. 2016;5:50–7.PubMed
40.
go back to reference Thamlikitkul L, Srimuninnimit V, Akewanlop C, et al. Efficacy of ginger for the prophylaxis of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adriamycin-cyclophosphamide regimen: a randomized, double-blind placebo-controlled crossover study. Support Care Cancer. 2017;25:459–64.CrossRef Thamlikitkul L, Srimuninnimit V, Akewanlop C, et al. Efficacy of ginger for the prophylaxis of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adriamycin-cyclophosphamide regimen: a randomized, double-blind placebo-controlled crossover study. Support Care Cancer. 2017;25:459–64.CrossRef
Metadata
Title
Nausea and Vomiting in Advanced Cancer
Author
Rudolph M. Navari, MD, PhD, FACP
Publication date
01-02-2020
Publisher
Springer US
Published in
Current Treatment Options in Oncology / Issue 2/2020
Print ISSN: 1527-2729
Electronic ISSN: 1534-6277
DOI
https://doi.org/10.1007/s11864-020-0704-8

Other articles of this Issue 2/2020

Current Treatment Options in Oncology 2/2020 Go to the issue

Palliative and Supportive Care (MP Davis, Section Editor)

Patient Spirituality as a Component of Supportive Care: Assessment and Intervention

Palliative and Supportive Care (MP Davis, Section Editor)

Cancer-Related Fatigue: Causes and Current Treatment Options

Palliative and Supportive Care (MP Davis, Section Editor)

How Effective Is Palliative Care in Improving Patient Outcomes?

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine